The effects of a novel potent oral retinoid (Rol3-6298) in the treatment of multiple solar keratoses and squamous cell epithelioma.
Sixteen patients with solar keratoses and/or squamous cell carcinoma were treated for 4 weeks with Rol3-6298, a potent oral retinoid of the arotinoid series. This treatment caused a small but statistically significant reduction in the mean number and area of the lesions. Tissue measurement and cell kinetic studies demonstrated that the treatment caused significant thickening of uninvolved epidermis but no change in the rate of cell division. Similar side-effects to those occurring with etretinate were experienced.
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007642:Keratosis / Q000188:drug therapy*; D008297:Male; D011230:Precancerous Conditions / Q000188:drug therapy*; D012176:Retinoids; D012878:Skin Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D001565:Benzoates; D012176:Retinoids; C034814:ethyl-p-((E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-1-propenyl)benzoic acid